The Digest’s 2026 Multi-Slide Guide to Codexis

Codexis is positioning its ECO Synthesis® platform to capture the growing RNAi therapeutics market, recently demonstrating process reproducibility with partners like Bachem and Nitto Avecia. Technical highlights include a new proprietary machine learning tool for optimized enzymatic ligation and the ability to control stereochemistry in siRNA synthesis. Commercially, the company reported a cash runway extending through Q1 2027 and is actively pursuing GMP scale-up partnerships while expanding its revenue-generating pharmaceutical biocatalysis business to support complex therapeutic manufacturing.